00:35 , Jun 13, 2019 |  BC Extra  |  Company News

Sobi buying Novimmune assets as it refocuses R&D

Less than a year after gaining an exclusive worldwide license for Gamifant emapalumab from Novimmune, Sobi is acquiring a newco formed around the hematology therapy for CHF515 million ($519.2 million) and restructuring its R&D pipeline...
19:25 , May 6, 2019 |  BC Innovations  |  Distillery Therapeutics

ADORA2A identified as a thrombosis target

DISEASE CATEGORY: Cardiovascular INDICATION: Thrombosis Cell culture and mouse studies suggest agonizing ADORA2A could help treat thrombosis. In primary human and mouse neutrophils treated with IgG from patients with antiphospholipid syndrome (APS), which is associated...
21:25 , May 1, 2019 |  BC Extra  |  Company News

Management tracks: Gilead, bluebird, Apollomics

Gilead Sciences Inc. (NASDAQ:GILD) said Robin Washington will retire as EVP and CFO, effective March 1, 2020. Washington, who joined Gilead in 2008, will continue in her role while the company identifies a successor. Gene...
19:11 , Mar 4, 2019 |  BC Innovations  |  Distillery Therapeutics

New bacteriophage-related therapeutic strategies for colitis and colorectal cancer

DISEASE CATEGORY: Cancer; gastrointestinal INDICATION: Colorectal cancer; colitis Patient sample and mouse studies suggest an E. coli bacteriophage cocktail could help treat bacteria-aggravated colorectal cancer and blockade of host-bacteriophage interactions via inhibition of IFNγ or...
00:23 , Jan 12, 2019 |  BioCentury  |  Finance

We all fall down

After an exuberant third quarter that put biotech indexes near their 2015 highs, all market cap tiers fell in 4Q18, eliminating the first nine month’s gains and losing $291.2 billion in aggregate value. Median losses...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
18:25 , Nov 30, 2018 |  BC Week In Review  |  Clinical News

On heels of Sobi deal, Novimmune's emapalumab gets FDA approval

FDA approved Gamifant emapalumab-lzsg from Novimmune S.A. (Plan-les-Ouates, Switzerland), giving Novimmune a Priority Review voucher and the first U.S.-approved drug for hemophagocytic lymphohistiocytosis (HLH). Novimmune said it plans to sell the Priority Review voucher. The...
20:53 , Nov 20, 2018 |  BC Extra  |  Company News

On heels of Sobi deal, Novimmune's emapalumab gets FDA approval

FDA approved Gamifant emapalumab-lzsg from Novimmune S.A. (Plan-les-Ouates, Switzerland), giving Novimmune a Priority Review voucher and the first U.S.-approved drug for hemophagocytic lymphohistiocytosis (HLH). The approval comes just four months after Swedish Orphan Biovitrum AB...
19:13 , Nov 16, 2018 |  BC Week In Review  |  Company News

Sobi springboards U.S. growth in deal for AZ's Synagis

Swedish Orphan Biovitrum AB (SSE:SOBI) obtained U.S. rights to commercialize infectious disease drug Synagis palivizumab from AstraZeneca plc (LSE:AZN; NYSE:AZN) for $1.5 billion up front. Sobi called the deal, which also includes profit sharing with...
21:40 , Nov 13, 2018 |  BC Extra  |  Company News

Sobi springboards U.S. growth in deal for AZ's Synagis

Swedish Orphan Biovitrum AB (SSE:SOBI) obtained U.S. rights to commercialize infectious disease drug Synagis palivizumab from AstraZeneca plc (LSE:AZN; NYSE:AZN) for $1.5 billion up front. Sobi called the deal, which also includes profit sharing with...